Department of Pathophysiology, Poznan University of Medical Sciences, Swiecickiego 6, 60-781, Poznan, Poland.
Clin Res Cardiol. 2010 May;99(5):315-22. doi: 10.1007/s00392-010-0122-1. Epub 2010 Feb 7.
Monocyte chemoattractant protein-1 (MCP-1) plays a key role in the pathogenesis of atherosclerosis and has been proposed as a biomarker for patients with cardiovascular disease.
To assess its clinical usefulness, serum MCP-1 concentrations were measured in patients with ST-elevation myocardial infarction (MI) at admission, immediately after percutaneous coronary intervention (PCI), at 24 h, and after 6 months.
We found no differences in MCP-1 concentrations between patients with acute MI, patients with stable coronary artery disease and healthy individuals. Although median MCP-1 concentrations in patients with MI were similar at admission and after 6 months, there were significant differences between individuals in how MCP-1 levels changed with time. As demonstrated by comparing baseline quartiles of MCP-1, the levels of MCP-1 tended to increase in patients with low MCP-1 concentration at admission, and decrease in patients with initially high MCP-1 levels. We found an inverse correlation between MCP-1 concentration at baseline and the time to reperfusion, and detected a significant decrease in MCP-1 concentration immediately after PCI. We also observed lower MCP-1 concentrations over time in patients who developed restenosis within 6 months. However, we did not confirm the association between MCP-1 concentrations at baseline and a number of previously implicated demographic, clinical and laboratory criteria.
Our data demonstrate some new aspects of MCP-1 measurement in patients with MI, but do not corroborate many earlier observations.
单核细胞趋化蛋白-1（MCP-1）在动脉粥样硬化的发病机制中起着关键作用，并被提议作为心血管疾病患者的生物标志物。
为了评估其临床实用性，在入院时、经皮冠状动脉介入治疗（PCI）后即刻、24 小时和 6 个月时测量 ST 段抬高型心肌梗死（MI）患者的血清 MCP-1 浓度。
我们发现在急性 MI 患者、稳定型冠状动脉疾病患者和健康个体之间，MCP-1 浓度没有差异。尽管 MI 患者的 MCP-1 中位数在入院时和 6 个月时相似，但个体间 MCP-1 水平随时间变化的差异很大。如通过比较 MCP-1 的基线四分位数，在入院时 MCP-1 浓度较低的患者中，MCP-1 水平趋于升高，而在初始 MCP-1 水平较高的患者中，MCP-1 水平下降。我们发现 MCP-1 浓度与再灌注时间之间存在负相关，并且在 PCI 后即刻 MCP-1 浓度显著下降。我们还观察到，在 6 个月内发生再狭窄的患者中，MCP-1 浓度随时间逐渐降低。然而，我们并未证实基线 MCP-1 浓度与之前提出的许多涉及人口统计学、临床和实验室标准的指标之间的关联。
我们的数据表明 MCP-1 在 MI 患者中的测量存在一些新的方面，但不能证实许多早期观察结果。
